PharmaLundensis AB engages in the provision of biotechnology activities. It offers research and development of medicines and treatment for lung diseases such as chronic obstructive pulmonary disease, chronic bronchitis, and influenza. The company was founded by Staffan Skogvall in 2006 and is headquartered in Lund, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company